Oprah Winfrey leaves WeightWatchers board, donates her shares and cites conflict of interest

Oprah Winfrey has told WeightWatchers she will not stand for re-election to its board of directors, the company said on Feb. 29, 2024, ending a run as a director that began in 2015. WW International stock dropped 25% in premarket trading that morning, and would be down 85% across six months if those early losses held ^[1].

Winfrey gave the company notice earlier in the week. Her current term runs out at the annual shareholder meeting scheduled for May 2024 — a year sooner than expected, since an extension she signed in 2019 reached into 2025 ^[1]. In a regulatory statement, WeightWatchers said her "decision was not the result of any disagreement" and did not concern "any matter relating to the company's operations, policies or practices" ^[1]. CEO Sima Sistani told investors on a call that Winfrey is "an inspiring presence and passionate advocate both for our members and for society at large" ^[1].

At the time, no explanation was given. On March 15, appearing on ABC's "Jimmy Kimmel Live!", Winfrey tied her exit to an ABC special she was preparing about these drugs. "I decided because this special was really important to me, and I wanted to be able to talk about whatever I want to talk about," she said. WeightWatchers "is now in the business of being a weight-health company that also administers drug medications for weight. I did not want to have the appearance of any conflict of interest" ^[2][3].

She is giving her entire stake in the company to the National Museum of African American History and Culture: about 1.1 million shares, or 1.43% of the company, worth roughly $2.5 million at the price then, according to FactSet figures reported by Variety. Her original purchase of 6.4 million shares cost $43.2 million ^[2]. The board backed the transfer and said it would happen during the March 2024 trading window; Winfrey also plans to hand the museum the proceeds from any future stock option exercises ^[2]. On Kimmel, she said the gift answered anyone who might claim she was "making money" off the special ^[3].

WeightWatchers has been rebuilding its offerings around the same drug category. It created a membership tier for people using GLP-1 medications that includes access to prescribing doctors, nutrition guidance, help with insurance and other support ^[1]. In 2023 the company bought Sequence, a telehealth subscription business that connects users with providers who can write weight-loss prescriptions, for $106 million ^[2]; CNN put the price at more than $100 million ^[1].

Winfrey said in December 2023, in an interview with People, that she had added a weight-loss medication to her routine without naming it ^[1][3]. She described having a medically approved prescription for managing weight as feeling "like relief, like redemption, like a gift" ^[3]. Which drug she uses, at what dose and for how long have not been disclosed ^[1][3].

The ABC program, "An Oprah Special: Shame, Blame and the Weight Loss Revolution," was taped in front of a live studio audience and pairs medical experts with patients to discuss Ozempic, Mounjaro and Wegovy, among other prescription weight-loss drugs ^[3]. The network said obesity costs $173 billion a year in US medical spending ^[3].

Why it matters for patients

The company Winfrey left looks different from the one she joined. Points-based coaching still exists, but WeightWatchers now sells a plan organized around prescription weight-loss medicine and owns a telehealth operation that routes patients to prescribers ^[1][2]. One of its best-known directors stepped away just as that strategy took hold ^[1][2].

Her explanation was about appearances rather than a dispute — she wanted room to discuss these medications on national television without a financial tie to a company that profits from them ^[1][2][3]. Money relationships among celebrities, telehealth prescribers and the companies selling these drugs are part of how patients encounter information about GLP-1s.

What is not public: the medication Winfrey takes, its dose or how long she has used it ^[1][3]. Whether the WeightWatchers GLP-1 membership, its price or its insurance help will change after her departure has not been reported ^[1][2].

What happens next

Her board term ends at the May 2024 shareholder meeting, where she will not be on the ballot ^[1]. The share donation was expected during the company's March 2024 trading window ^[2]. The special aired Monday, March 18, 2024, and streamed the following day on Hulu ^[3]. No successor for her seat has been announced ^[1][2].